Geron
Update in progressGERN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Geron Corporation is a commercial-stage biopharmaceutical company focused on oncology therapeutics. Its pipeline includes RYTELO, a telomerase inhibitor for adults with low- to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia; IMerge (Phase 3) for lower-risk MDS; IMpactMF (Phase 3) for relapsed/refractory myelofibrosis; Impress (Phase 2) for higher-risk MDS and AML; IMproveMF (Phase 1) for frontline myelofibrosis; and IMAGINE (Phase 1/2) for relapsed/refractory AML. Founded in 1990, based in Foster City, California.
Company score
- Sentiment
- -0.10
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.27
- Governance
- -0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.09
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!